Across TCGA pan-cancer cohorts, ACTR3BP2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ACTR3BP2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ACTR3BP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTR3BP2 expression acts as an unfavorable survival marker.

BLCA and ACC are the cancer types where ACTR3BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.015	0.616	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ACTR3BP2 tumor-vs-normal RNA expression · all ACTR3BP2 data types